What You Should Know:
– Merck Global Health Innovation Fund (MGHIF), a leader in healthcare impact investing, announced a strategic investment in Qure.ai, a prominent developer of artificial intelligence (AI) solutions for medical imaging.
– The strategic investment fuels Qure.ai’s Series D funding round and propels their mission of expanding access to AI-powered imaging technology globally.
Expanding Reach and Capabilities
The funding will be directed towards two key areas:
- Foundation models for AI in imaging: This investment aims to strengthen the core technology behind Qure.ai’s AI algorithms, paving the way for even more sophisticated medical imaging analysis.
- U.S. market expansion: Qure.ai will leverage the funding to broaden the reach of its AI solutions into the United States healthcare system.
Global Impact: AI for Earlier Disease Detection
Qure.ai has already established a significant presence, deploying AI-powered solutions for tuberculosis (TB), lung cancer, and stroke detection across over 2,700 imaging facilities in more than 90 countries. Notably, they hold FDA clearance for their qXR-LN chest X-ray lung nodule detection solution and have received breakthrough device designation for their TB solution (qSpot-TB).
Addressing Growing Healthcare Needs
With rising patient populations and increasing pressure on healthcare systems, AI presents a tremendous opportunity for early disease detection and improved patient management.“Healthcare AI provides the opportunity to review people faster as we have shown in patients with TB in low-and middle-income countries, as well as lung cancer and emergency triage in the UK’s National Health Service,” said Prashant Warier, Co-founder and CEO of Qure.ai. “This strategic investment in Qure.ai from the Merck Global Health Innovation Fund will enable us to expedite our work in foundation models and expand the reach of our AI both geographically and demographically.”
